Lubilax 24 mcg (Capsule)
Medicine Details
| Category | Details |
|---|---|
| Generic | Lubiprostone |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Title
Lubilax Medicine
Categories
- Digestive Health
- Medicine
- Laxatives
Description
Lubilax is a medicine indicated for Irritable Bowel Syndrome with Constipation (IBS-C), Chronic Idiopathic Constipation (CIC) in adults, and Opioid-Induced Constipation (OIC) in adult patients with chronic, non-cancer pain. It is a locally-acting chloride-channel activator that increases intestinal secretion, thus aiding the passage of stool and relieving the symptoms associated with chronic idiopathic constipation.
Indications
- Irritable Bowel Syndrome with Constipation (IBS-C)
- Chronic Idiopathic Constipation (CIC) in adults
- Opioid-Induced Constipation (OIC) in adult patients with chronic, non-cancer pain
Pharmacology
Lubiprostone is a chloride-channel activator that increases intestinal secretion, leading to increased intestinal motility and aiding the passage of stool. It specifically activates ClC-2 chloride channels, causing an efflux of chloride ions into the lumen and leading to an efflux of sodium ions through a paracellular pathway, thereby increasing intestinal fluid secretion and motility in the intestine.
DosageAdministration
- Irritable Bowel Syndrome with Constipation: 8 mcg twice daily orally with food and water
- Dosage in patients with hepatic impairment: Dosage adjustment is not required for patients with moderately impaired hepatic function. For severely impaired hepatic function, the recommended starting dose is 8 mcg once daily
Interaction
There is a possibility of a dose-dependent decrease in the efficacy of Lubilax in patients using diphenylheptane opioids
Contraindications
Lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction
SideEffects
- Diarrhea
- Full or bloated feeling or pressure in the stomach
- Nausea
- Stomach pain
- Swelling of abdominal or stomach area
- Dyspnea
PregnancyLactation
Pregnancy category C. It is not known whether lubiprostone is excreted in human milk. Caution should be exercised when Lubiprostone is administered to a nursing woman
PrecautionsWarnings
- Nausea: Patients taking Lubilax may experience nausea. Concomitant administration of food with Lubilax may reduce symptoms of nausea
- Diarrhea: Lubistone should not be prescribed to patients that have severe diarrhea
- Bowel Obstruction: In patients with symptoms suggestive of mechanical gastrointestinal obstruction, confirm the absence of an obstruction prior to initiating therapy with Lubilax
OverdoseEffects
Adverse reactions due to overdose may include nausea, diarrhea, vomiting, dizziness, headache, abdominal pain, flushing/hot flash, retching, dyspnea, pallor, stomach discomfort, anorexia, asthenia, chest discomfort, dry mouth, hyperhidrosis, and syncope
TherapeuticClass
Other laxative preparations
StorageConditions
Store between 15-30°C